Baird initiated coverage of Amylyx Pharmaceuticals with an Outperform rating and $37 price target. The analyst models a 40% probability of success for the phase 3 PHOENIX trial of Relyvrio in amyotrophic lateral sclerosis, which has topline results expected in Q2. The stock could quadruple if PHOENIX succeeds, while downside risk might not exceed 30% if the trial fails, the analyst tells investors in a research note. The firm sees a favorable risk/reward heading into the Phase 3 data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMLX:
- Amylyx announces first patient dosed in ORION trial
- Mizuho lowers Amylyx price target to $27, calls ‘a top pick for 2024’
- These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank
- Amylyx initiated with bullish view at Deutsche Bank, here’s why
- Amylyx announces data showing effect of AMX0035 on biomarkers in ALS
